Sparing of contralateral major salivary glands has a significant effect on oral health in patients treated with radical radiotherapy of head and neck tumors

Strahlentherapie und Onkologie

Volumn 178, Issue 12, 2002, Pages 722-726

  Beer, Karl T ^a   Zehnder, Diego ^a   Lussi, Adrian ^a   Greiner, Richard H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Buffer capacity; ENT tumors; PH; Radiotherapy; Saliva flow; Salivary glands; Streptococcus mutans

Indexed keywords

BUFFER;

ADULT; AGED; ALKALINITY; ARTICLE; BACTERIAL COLONIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONVALESCENCE; EVALUATION; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MOUTH CAVITY; PAROTID GLAND; PH MEASUREMENT; RADIATION DOSE; RADIATION SHIELD; SALIVARY GLAND; SALIVATION; STREPTOCOCCUS MUTANS; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND;

ADULT; AGED; CELL COUNT; DENTAL CARIES SUSCEPTIBILITY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ORAL HEALTH; OTORHINOLARYNGOLOGIC NEOPLASMS; PAROTID GLAND; RADIATION INJURIES; RADIATION PROTECTION; SALIVATION; STREPTOCOCCUS MUTANS; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND;

EID: 18744411221     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-0961-4     Document Type: Article

References (26)

1. Bratengeier K. Applications of two-step intensity modulated arc therapy. Strahlther Onkol 2001;177:394-403.
2. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monier A, Eschwege F, Zang J, Russel L, Oster W, Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18: 3339-45.
3. Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, Low DA. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 2001;49;907-16.
4. Eisbruch A, Dawson LA, Kim HM, Bradford CR, Terrell JE, Chepeha DB, Teknos TN, Anzai Y, Marsh LH, Martel MK, Ten Haken RK, Wolf GT, Ship JA. Conformal and intensity modulated irradiation of head and neck cancer: The potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg 1999;53:271-5.
5. Eisbruch A, Ship JA, Kim HM, Ten Haken RK. Partial irradiation of the major salivary gland. Semin Radiat Oncol 2001;11:234-9.
6. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45:577-87.
7. Franzen L, Funegård, Ericson T, Hendriksson R. Major salivary gland function during and following radiotherapy of malignancies in the head and neck. Eur J Cancer 1992;28:457-62.
8. Grötz KA, Duschner H, Kutzner J, Theten M, Wagner W. Neue erkenntnisse zur aetiologie der sogenannten strahlenkaries. Strahlenther Onkol 1997; 173:668-76.
9. Grötz KA, Henneicke-von Zepetin HH, Kohnen R, Al-Nawas B, Bockisch A, Kutzner J, Wüstenberg P, Naser-Hijazi B, Belz GG, Wagner W. Prospektive, doppelblinde therapiestudie zur prophylaxe der radioxerostomie durch cumarin/troxerutin bei patienten mit kopf-hals-karzinomen. Strahlenther Onkol 1999;175:397-403.
10. Grotz KA, Riesenbeck D, Brahm R, Seegenschmiedt MH, Al-Nawas B, Dorr W, Kutzner J, Willich N, Thelen M Wagner W. Chronische strahlenfolgen an den zahnhartgeweben ("strahlenkaries"): klassifikation und behandlungsansätze. Strahlenther Onkol 2001;177:96-104.
11. Hazuka MB, Martel MK, Marsh L, Lichter AS, Wolf GT. Preservation of parotid function after external beam irradiation in head and neck cancer patients: A feasibilty study using 3-dimensional treatment planning. Int J Radial Oncol Biol Phys 1993;27:731-7.
12. Horiot JC, Lipinski FV, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, Bolla M, Coscas F, Baillet F, Coche-Dequéant B, Urbajtel M, Montbarbon X, Bourdin S, Wibault P, Alfonsi M, Calais G, Desprez P, Pene F, Lapeyre M, Vinke J, Maral J. Postradiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiol Oncol 2000;55:233-9.
13. Hug EB, Slater JD. Proton radiation therapy for pediatric malignancies: Status report. Strahlenther Onkol 1999;175:Suppl 2:89-91.
14. Janda M, Johnson D, Woelfli H, Trimmel M, Bressmann T, Schrockmayr H, Widder J, Trotti A. Measurement of quality of life in head and neck cancer patients utitizing the quality of life radiation therapy questionnaire. Strahlenther Onkol 2002;178:153-8.
15. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, Gallagher SC. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
16. Keene HJ, Fleming TJ. Prevalence of caries-associated microflora after radiotherapy in patients with cancer of the head and neck. Oral Surg Oral Med Oral Pathol 1987;64:421-6.
17. Markitziu A, Zafiropoulos G, Tsalikis L, Cohen L. Gingival health and salivary function in head and neck-irradiated patients. Oral Surg Oral Med Oral Pathol 1992;73:427-33.
18. Niedermeier W, Matthaeus C, Meyer C, Staar S, Müller RP, Schulze HJ. Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:541-9.
19. Nutting CM, Rowbottom CG, Cosgrove VP, Dearnaley DP, Robinson MH, Conway J, Webb S. Optimisation of radiotherapy for carcinoma of the major salivary grand comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother Onol 2001;60:163-72.
20. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, Muscoplat CC, Gallagher S. Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety resutts from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys 1995;31:661-8.
21. Rodemann HP, Hehr T, Bamberg M. Relevance of the radioprotective effect of natrium selenit. Preclinical results. Med Klin 1999;94:Suppl III:39-41.
22. Schultze J, Kimmig B. Ergebnisse der primären radiochemotherapie von kopf-hals-tumoren mit simuttaner speicheldrüsenprotektion durch amifostine. Strahlenther Onkol 1999;175:Suppl IV:13-7.
23. Slarer JM, Slater JD, Archambeau JO Carcinoma of the tonsittar region: Potential for use of proton beam therapy. Int J Radiat Oncol Biol Phys 1992;22:311-9.
24. Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlenther Onkol 1999;175:Suppl 4:18-22.
25. Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modutated radiation treatments of head and neck cancers: A treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195-205.
26. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998;8:107-14.